President and CEO @ Nonclinical Safety Solutions LLC (May 2014 - Present)
Director, Preclinical Safety @ ARIAD Pharmaceuticals, Inc. (June 2013 - May 2014)
Associate Vice President, Nonclinical Safety @ ImClone Systems, a wholly-owned subsidiary of Eli Lilly, (January 2009 - May 2013)
Head, Science and Strategy @ (January 2003 - January 2008)
Research Leader, Project Team Toxicologist @ (January 1998 - January 2003)
Pharmacologist and Toxicologist @ (January 1995 - January 1998)
Senior Research Neuroscientist @ Interneuron Pharmaceuticals (January 1992 - January 1994)
Post-Doctoral Fellow, Neurology @ (January 1990 - January 1992)
Post-Doctoral Fellow, Physiology @ (January 1988 - January 1990)
Thomas Steele Education
Purdue University
Doctor of Philosophy (Ph.D.) (Pharmacology and Toxicology)
1986-1988
Purdue University
Master of Science (MS) (Pharmacology and Toxicology)
1983-1986
Thomas Steele Skills
Drug Development
Drug Discovery
Pharmaceutical Industry
Clinical Development
Clinical Trials
Biotechnology
Life Sciences
Pharmacology
Regulatory Submissions
In Vivo
Solutions
Customer Service
Data Analysis
Business Strategy
Drug Safety
Healthcare
Clinical Research
CRO
Biopharmaceuticals
Teaching
Microsoft Excel
Thomas Steele Summary
Thomas Steele, based in Boston, MA, US, is currently a President and CEO Nonclinical Safety Solutions LLC at Nonclinical Safety Solutions. Thomas Steele brings experience from previous roles at Reveal Pharmaceuticals, Nonclinical Safety Solutions LLC, ARIAD Pharmaceuticals, Inc. and ImClone Systems, a wholly-owned subsidiary of Eli Lilly,. Thomas Steele holds a 1986 - 1988 Doctor of Philosophy (Ph.D.) in Pharmacology and Toxicology @ Purdue University. With a robust skill set that includes Drug Development, Drug Discovery, Pharmaceutical Industry, Clinical Development, Clinical Trials and more. Thomas Steele has 1 emails and 1 mobile phone numbers on RocketReach.
Looking for a different Thomas Steele?
Find contact details for 700 million professionals.